APA (7th ed.) Citation

Nasser, A. F., Heidbreder, C., Liu, Y., & Fudala, P. J. (2015). Pharmacokinetics of Sublingual Buprenorphine and Naloxone in Subjects with Mild to Severe Hepatic Impairment (Child-Pugh Classes A, B, and C), in Hepatitis C Virus-Seropositive Subjects, and in Healthy Volunteers. Clinical pharmacokinetics, 54(8), 837-849. https://doi.org/10.1007/s40262-015-0238-6

Chicago Style (17th ed.) Citation

Nasser, Azmi F., Christian Heidbreder, Yongzhen Liu, and Paul J. Fudala. "Pharmacokinetics of Sublingual Buprenorphine and Naloxone in Subjects with Mild to Severe Hepatic Impairment (Child-Pugh Classes A, B, and C), in Hepatitis C Virus-Seropositive Subjects, and in Healthy Volunteers." Clinical Pharmacokinetics 54, no. 8 (2015): 837-849. https://doi.org/10.1007/s40262-015-0238-6.

MLA (9th ed.) Citation

Nasser, Azmi F., et al. "Pharmacokinetics of Sublingual Buprenorphine and Naloxone in Subjects with Mild to Severe Hepatic Impairment (Child-Pugh Classes A, B, and C), in Hepatitis C Virus-Seropositive Subjects, and in Healthy Volunteers." Clinical Pharmacokinetics, vol. 54, no. 8, 2015, pp. 837-849, https://doi.org/10.1007/s40262-015-0238-6.